{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:59:43Z","timestamp":1790539183417,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T00:00:00Z","timestamp":1600214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T00:00:00Z","timestamp":1600214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100003156","name":"Musella Foundation For Brain Tumor Research and Information","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100003156","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"crossref","award":["P30CA012197"],"award-info":[{"award-number":["P30CA012197"]}],"id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"crossref"}]},{"name":"U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute","award":["P30CA012197-39"],"award-info":[{"award-number":["P30CA012197-39"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hypoxia inducible factor (HIFs) signaling contributes to malignant cell behavior in glioblastoma (GBM). We investigated a novel HIF2\u03b1 inhibitor, PT2385, both in vitro<jats:italic>,<\/jats:italic> with low-passage patient-derived cell lines, and in vivo, using orthotopic models of glioblastoma. We focused on analysis of HIF2\u03b1 expression in situ, cell survival\/proliferation, and survival in brain tumor-bearing mice treated with PT2385 alone and in combination with standard of care chemoradiotherapy. HIF2\u03b1 expression increased with glioma grade, with over half of GBM specimens HIF2\u03b1 positive. Staining clustered in perivascular and perinecrotic tumor regions. Cellular phenotype including proliferation, viability, migration\/invasion, and also gene expression were not altered after PT2385 treatment. In the animal model, PT2385 single-agent treatment did improve median overall survival compared to placebo (<jats:italic>p<\/jats:italic>\u2009=\u20090.04, n\u2009=\u200921) without a bioluminescence correlate (t\u2009=\u20090.67, <jats:italic>p<\/jats:italic>\u2009=\u20090.52). No difference in animal survival was seen in combination treatment with radiation (RT)\/temozolomide (TMZ)\/PT2385 (<jats:italic>p<\/jats:italic>\u2009=\u20090.44, n\u2009=\u200910) or mean tumor bioluminescence (t 1.13, <jats:italic>p<\/jats:italic>\u2009=\u20090.32). We conclude that HIF2\u03b1 is a reasonable novel therapeutic target as expressed in the majority of glioblastomas in our cohort. PT2385 as a single-agent was efficacious in vivo, however, an increase in animal survival was not seen with PT2385 in combination with RT\/TMZ. Further study for targeting HIF2\u03b1 as\u00a0a therapeutic approach in GBM is warranted.<\/jats:p>","DOI":"10.1038\/s41598-020-72290-2","type":"journal-article","created":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T10:03:22Z","timestamp":1600250602000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor"],"prefix":"10.1038","volume":"10","author":[{"given":"Jaclyn J.","family":"Renfrow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Soike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakti H.","family":"Ramkissoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Metheny-Barlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan T.","family":"Mott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A.","family":"Kittel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Ralph B.","family":"D\u2019Agostino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B.","family":"Tatter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4631-5476","authenticated-orcid":false,"given":"Adrian W.","family":"Laxton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark B.","family":"Frenkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Herpai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7489-4885","authenticated-orcid":false,"given":"Jann N.","family":"Sarkaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn J.","family":"Lesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waldemar","family":"Debinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy E.","family":"Strowd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,16]]},"reference":[{"key":"72290_CR1","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/ki.1997.77","volume":"51","author":"GL Semenza","year":"1997","unstructured":"Semenza, G. L. et al. Structural and functional analysis of hypoxia-inducible factor 1. Kidney Int. 51, 553\u2013555 (1997).","journal-title":"Kidney Int."},{"key":"72290_CR2","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1101\/gad.1881410","volume":"24","author":"N Takeda","year":"2010","unstructured":"Takeda, N. et al. Differential activation and antagonistic function of HIF-{alpha} isoforms in macrophages are essential for NO homeostasis. Genes Dev. 24, 491\u2013501 (2010).","journal-title":"Genes Dev."},{"key":"72290_CR3","first-page":"205","volume":"7","author":"YZ Gu","year":"1998","unstructured":"Gu, Y. Z., Moran, S. M., Hogenesch, J. B., Wartman, L. & Bradfield, C. A. Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene Exp. 7, 205\u2013213 (1998).","journal-title":"Gene Exp."},{"key":"72290_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/10409238.2013.838205","volume":"49","author":"VL Dengler","year":"2014","unstructured":"Dengler, V. L., Galbraith, M. D. & Espinosa, J. M. Transcriptional regulation by hypoxia inducible factors. Crit. Rev. Biochem. Mol. Biol. 49, 1\u201315 (2014).","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"72290_CR5","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.trecan.2017.05.002","volume":"3","author":"S Rey","year":"2017","unstructured":"Rey, S., Schito, L., Wouters, B. G., Eliasof, S. & Kerbel, R. S. Targeting hypoxia-inducible factors for antiangiogenic cancer therapy. Trends Cancer 3, 529\u2013541 (2017).","journal-title":"Trends Cancer"},{"key":"72290_CR6","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.semcdb.2005.03.007","volume":"169","author":"H Axelson","year":"2005","unstructured":"Axelson, H., Fredlund, E., Ovenberger, M., Landberg, G. & Pahlman, S. Hypoxia-induced dedifferentiation of tumor cells\u2014A mechanism behind heterogeneity and aggressiveness of solid tumors. Semi Cell Dev. Biol. 169, 554\u201363 (2005).","journal-title":"Semi Cell Dev. Biol."},{"key":"72290_CR7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrc704","volume":"2","author":"AL Harris","year":"2002","unstructured":"Harris, A. L. Hypoxia\u2014A key regulatory factor in tumour growth. Nat. Rev. Cancer 2, 38\u201347 (2002).","journal-title":"Nat. Rev. Cancer"},{"key":"72290_CR8","doi-asserted-by":"publisher","first-page":"3274","DOI":"10.4161\/cc.8.20.9701","volume":"8","author":"JM Heddleston","year":"2009","unstructured":"Heddleston, J. M., Li, Z., McLendon, R. E., Hjelmeland, A. B. & Rich, J. N. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 8, 3274\u20133284 (2009).","journal-title":"Cell Cycle"},{"key":"72290_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc3183","volume":"12","author":"B Keith","year":"2012","unstructured":"Keith, B., Johnson, R. S. & Simon, M. C. HIF1\u03b1 and HIF2\u03b1: sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 12, 9\u201322 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"72290_CR10","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3349\/ymj.2017.58.3.489","volume":"58","author":"T Yu","year":"2017","unstructured":"Yu, T., Tang, B. & Sun, X. Development of inhibitors targeting hypoxia-inducible factor 1 and 2 for cancer therapy. Yonsei Med. J. 58, 489 (2017).","journal-title":"Yonsei Med. J."},{"key":"72290_CR11","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1080\/0284186X.2017.1301680","volume":"56","author":"S Soni","year":"2017","unstructured":"Soni, S. & Padwad, Y. S. HIF-1 in cancer therapy: Two decade long story of a transcription factor. Acta Oncol. 56, 503\u2013515 (2017).","journal-title":"Acta Oncol."},{"key":"72290_CR12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejmech.2012.01.033","volume":"49","author":"Y Xia","year":"2012","unstructured":"Xia, Y., Choi, H.-K. & Lee, K. Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. Eur. J. Med. Chem. 49, 24\u201340 (2012).","journal-title":"Eur. J. Med. Chem."},{"key":"72290_CR13","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1200\/JCO.2017.74.2627","volume":"36","author":"KD Courtney","year":"2018","unstructured":"Courtney, K. D. et al. Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2\u03b1 antagonist in patients with previously treated advanced clear cell renal cell carcinoma. J. Clin. Oncol. 36, 867\u2013874 (2018).","journal-title":"J. Clin. Oncol."},{"key":"72290_CR14","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1097\/00005072-200606000-00001","volume":"65","author":"Y Rong","year":"2006","unstructured":"Rong, Y., Durden, D. L., Van Meir, E. G. & Brat, D. J. \u2018Pseudopalisading\u2019 necrosis in glioblastoma: A familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J. Neuropathol. Exp. Neurol. 65, 529\u2013539 (2006).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"72290_CR15","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ccr.2009.03.018","volume":"15","author":"Z Li","year":"2009","unstructured":"Li, Z. et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 15, 501\u2013513 (2009).","journal-title":"Cancer Cell"},{"key":"72290_CR16","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.4155\/fmc-2018-0163","volume":"10","author":"JJ Renfrow","year":"2018","unstructured":"Renfrow, J. J. et al. Hypoxia-inducible factor 2\u03b1: A novel target in gliomas. Fut. Med. Chem. 10, 2227\u20132236 (2018).","journal-title":"Fut. Med. Chem."},{"key":"72290_CR17","doi-asserted-by":"publisher","first-page":"15504","DOI":"10.1073\/pnas.2533374100","volume":"100","author":"PJA Erbel","year":"2003","unstructured":"Erbel, P. J. A., Card, P. B., Karakuzu, O., Bruick, R. K. & Gardner, K. H. Structural basis for PAS domain heterodimerization in the basic helix-loop-helix-PAS transcription factor hypoxia-inducible factor. Proc. Natl. Acad. Sci. 100, 15504\u201315509 (2003).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"72290_CR18","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1073\/pnas.0808092106","volume":"106","author":"TH Scheuermann","year":"2009","unstructured":"Scheuermann, T. H. et al. Artificial ligand binding within the HIF2 PAS-B domain of the HIF2 transcription factor. Proc. Natl. Acad. Sci. 106, 450\u2013455 (2009).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"72290_CR19","doi-asserted-by":"crossref","unstructured":"Courtney, K. et al. A phase I dose escalation trial of PT2385, a first-in-class oral HIF-2a inhibitor, in patients with advanced clear cell renal cell carcinoma, in ASCO Meeting Abstracts (2016).","DOI":"10.1200\/JCO.2016.34.15_suppl.2506"},{"key":"72290_CR20","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-0473","author":"EM Wallace","year":"2008","unstructured":"Wallace, E. M. et al. A small-molecule antagonist of HIF2a is efficacious in preclinical models of renal cell carcinoma. Ther. Targets Chem. Biol. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-0473 (2008).","journal-title":"Ther. Targets Chem. Biol."},{"key":"72290_CR21","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1158\/1541-7786.MCR-05-0056","volume":"3","author":"J Wykosky","year":"2005","unstructured":"Wykosky, J., Gibo, D. M., Stanton, C. & Debinski, W. EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol. Cancer Res. 3, 541\u2013551 (2005).","journal-title":"Mol. Cancer Res."},{"key":"72290_CR22","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s11060-013-1321-1","volume":"116","author":"WH Gmeiner","year":"2014","unstructured":"Gmeiner, W. H. et al. Selective anti-tumor activity of the novel fluoropyrimidine polymer F10 towards G48a orthotopic GBM tumors. J. Neurooncol. 116, 447\u2013454 (2014).","journal-title":"J. Neurooncol."},{"key":"72290_CR23","doi-asserted-by":"publisher","first-page":"610","DOI":"10.3171\/JNS-07\/09\/0610","volume":"107","author":"EB Dinca","year":"2007","unstructured":"Dinca, E. B. et al. Bioluminescence monitoring of intracranial glioblastoma xenograft: Response to primary and salvage temozolomide therapy. J. Neurosurg. 107, 610\u2013616 (2007).","journal-title":"J. Neurosurg."},{"key":"72290_CR24","doi-asserted-by":"publisher","DOI":"10.3791\/1986","author":"T Ozawa","year":"2010","unstructured":"Ozawa, T. & James, C. D. Establishing intracranial brain tumor xenografts with subsequent analysis of tumor growth and response to therapy using bioluminescence imaging. J. Vis. Exp. https:\/\/doi.org\/10.3791\/1986 (2010).","journal-title":"J. Vis. Exp."},{"key":"72290_CR25","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1093\/bioinformatics\/bts196","volume":"28","author":"DS DeLuca","year":"2012","unstructured":"DeLuca, D. S. et al. RNA-SeQC: RNA-seq metrics for quality control and process optimization. Bioinformatics 28, 1530\u20131532 (2012).","journal-title":"Bioinformatics"},{"key":"72290_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: Ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"72290_CR27","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"72290_CR28","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1186\/1471-2105-12-480","volume":"12","author":"D Risso","year":"2011","unstructured":"Risso, D., Schwartz, K., Sherlock, G. & Dudoit, S. GC-content normalization for RNA-Seq data. BMC Bioinform. 12, 480 (2011).","journal-title":"BMC Bioinform."},{"key":"72290_CR29","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/nbt.2931","volume":"32","author":"D Risso","year":"2014","unstructured":"Risso, D., Ngai, J., Speed, T. P. & Dudoit, S. Normalization of RNA-seq data using factor analysis of control genes or samples. Nat. Biotechnol. 32, 896\u2013902 (2014).","journal-title":"Nat. Biotechnol."},{"key":"72290_CR30","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/bioinformatics\/btt703","volume":"30","author":"A Kr\u00e4mer","year":"2014","unstructured":"Kr\u00e4mer, A., Green, J., Pollard, J. & Tugendreich, S. Causal analysis approaches in ingenuity pathway analysis. Bioinformatics 30, 523\u2013530 (2014).","journal-title":"Bioinformatics"},{"key":"72290_CR31","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/neuonc\/now258","volume":"19","author":"N Colwell","year":"2017","unstructured":"Colwell, N. et al. Hypoxia in the glioblastoma microenvironment: Shaping the phenotype of cancer stem-like cells. Neuro. Oncol. 19, 887\u2013896 (2017).","journal-title":"Neuro. Oncol."},{"key":"72290_CR32","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1097\/MNM.0b013e3283529984","volume":"33","author":"Y Yamamoto","year":"2012","unstructured":"Yamamoto, Y. et al. Hypoxia assessed by 18F-fluoromisonidazole positron emission tomography in newly diagnosed gliomas. Nucl. Med. Commun. 33, 621\u2013625 (2012).","journal-title":"Nucl. Med. Commun."},{"key":"72290_CR33","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/00006123-200207000-00002","volume":"51","author":"SM Raza","year":"2002","unstructured":"Raza, S. M. et al. Necrosis and glioblastoma: A friend or a foe? A review and a hypothesis. Neurosurgery 51, 2\u201312 (2002). (discussion 12\u201313).","journal-title":"Neurosurgery"},{"key":"72290_CR34","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1158\/1535-7163.MCT-15-0675","volume":"15","author":"G Lee","year":"2016","unstructured":"Lee, G. et al. Dedifferentiation of glioma cells to glioma stem-like cells by therapeutic stress-induced HIF signaling in the recurrent GBM model. Mol. Cancer Ther. 15, 3064\u20133076 (2016).","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"72290_CR35","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/cells6040045","volume":"6","author":"AR Monteiro","year":"2017","unstructured":"Monteiro, A. R., Hill, R., Pilkington, G. J. & Madureira, P. A. The role of hypoxia in glioblastoma invasion. Cells 6(4), 45 (2017).","journal-title":"Cells"},{"key":"72290_CR36","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10978","author":"S Ferluga","year":"2016","unstructured":"Ferluga, S., Tom\u00e9, C. M. L., Herpai, D. M., D\u2019Agostino, R. & Debinski, W. Simultaneous targeting of Eph receptors in glioblastoma. Oncotarget https:\/\/doi.org\/10.18632\/oncotarget.10978 (2016).","journal-title":"Oncotarget"},{"key":"72290_CR37","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1200\/JCO.2007.13.3652","volume":"26","author":"S Sathornsumetee","year":"2008","unstructured":"Sathornsumetee, S. et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J. Clin. Oncol. 26, 271\u2013278 (2008).","journal-title":"J. Clin. Oncol."},{"key":"72290_CR38","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1038\/labinvest.2011.56","volume":"91","author":"X Mao","year":"2011","unstructured":"Mao, X. et al. Overexpression of ZNF217 in glioblastoma contributes to the maintenance of glioma stem cells regulated by hypoxia-inducible factors. Lab. Investig. 91, 1068\u20131078 (2011).","journal-title":"Lab. Investig."},{"key":"72290_CR39","doi-asserted-by":"publisher","first-page":"E83","DOI":"10.1371\/journal.pbio.0000083","volume":"1","author":"K Kondo","year":"2003","unstructured":"Kondo, K., Kim, W. Y., Lechpammer, M. & Kaelin, W. G. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 1, E83 (2003).","journal-title":"PLoS Biol."},{"key":"72290_CR40","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1158\/1541-7786.89.2.2","volume":"2","author":"M Zimmer","year":"2004","unstructured":"Zimmer, M., Doucette, D., Siddiqui, N. & Iliopoulos, O. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL\u2212\/\u2212 tumors. Mol. Cancer Res. 2, 89\u201395 (2004).","journal-title":"Mol. Cancer Res."},{"key":"72290_CR41","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1124\/jpet.102.038554","volume":"303","author":"MM Belcheva","year":"2002","unstructured":"Belcheva, M. M., Haas, P. D., Tan, Y., Heaton, V. M. & Coscia, C. J. The fibroblast growth factor receptor is at the site of convergence between mu-opioid receptor and growth factor signaling pathways in rat C6 glioma cells. J. Pharmacol. Exp. Ther. 303, 909\u2013918 (2002).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"72290_CR42","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997\u20131003 (2005).","journal-title":"N. Engl. J. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-72290-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-72290-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-72290-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T19:34:33Z","timestamp":1670355273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-72290-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,16]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["72290"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-72290-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,16]]},"assertion":[{"value":"13 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15195"}}